These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 30337220

  • 21. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
    Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Miguelez CG, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick AR, Fietkau R, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Pötter R, Gall C, Uter W, Strnad V, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO).
    Lancet Oncol; 2017 Feb; 18(2):259-268. PubMed ID: 28094198
    [Abstract] [Full Text] [Related]

  • 22. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M.
    Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
    [Abstract] [Full Text] [Related]

  • 23. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.
    Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF.
    Lancet Oncol; 2015 Sep; 16(9):1049-1060. PubMed ID: 26206146
    [Abstract] [Full Text] [Related]

  • 24. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
    EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.
    Lancet; 2014 Jun 21; 383(9935):2127-35. PubMed ID: 24656685
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, Zhang N, Hanes V.
    Lancet Oncol; 2018 Jul 21; 19(7):987-998. PubMed ID: 29880292
    [Abstract] [Full Text] [Related]

  • 26. An assessment of quality of life for early phase after adjuvant radiotherapy in breast cancer survivors: a Korean multicenter survey (KROG 14-09).
    Rim CH, Ahn SJ, Kim JH, Yoon WS, Chun M, Yang DS, Lee JH, Kim K, Kong M, Kim S, Kim J, Park KR, Shin YJ, Ma SY, Jeong BK, Kim SS, Kim YB, Lee DS, Cha J.
    Health Qual Life Outcomes; 2017 May 10; 15(1):96. PubMed ID: 28486990
    [Abstract] [Full Text] [Related]

  • 27. POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes.
    Goyal A, Mann GB, Fallowfield L, Duley L, Reed M, Dodwell D, Coleman RE, Fakis A, Newcombe R, Jenkins V, Whitham D, Childs M, Whynes D, Keeley V, Ellis I, Fairbrother P, Sadiq S, Monson K, Montgomery A, Tan W, Vale L, Homer T, Badger H, Haines RH, Lewis M, Megias D, Nabi Z, Singh P, Caraman A, Miles E, POSNOC Trialists.
    BMJ Open; 2021 Dec 02; 11(12):e054365. PubMed ID: 34857578
    [Abstract] [Full Text] [Related]

  • 28. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M, CRITICS investigators.
    Lancet Oncol; 2018 May 02; 19(5):616-628. PubMed ID: 29650363
    [Abstract] [Full Text] [Related]

  • 29. POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial.
    Zhao XR, Fang H, Tang Y, Hu ZH, Jing H, Liang L, Yan XN, Song YW, Jin J, Liu YP, Chen B, Tang Y, Qi SN, Li N, Lu NN, Men K, Hu C, Zhang YH, Li YX, Wang SL.
    BMC Cancer; 2021 Nov 06; 21(1):1185. PubMed ID: 34742270
    [Abstract] [Full Text] [Related]

  • 30. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
    Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, Budrukkar A, Mittra I, Gupta S.
    Lancet Oncol; 2015 Oct 06; 16(13):1380-8. PubMed ID: 26363985
    [Abstract] [Full Text] [Related]

  • 31. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.
    Adamson D, Byrne A, Porter C, Blazeby J, Griffiths G, Nelson A, Sewell B, Jones M, Svobodova M, Fitzsimmons D, Nixon L, Fitzgibbon J, Thomas S, Millin A, Crosby T, Staffurth J, Hurt C.
    Lancet Gastroenterol Hepatol; 2021 Apr 06; 6(4):292-303. PubMed ID: 33610215
    [Abstract] [Full Text] [Related]

  • 32. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial.
    Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, McCartney A, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Walsh T, Sykes P, Ngan H, Garrett A, Laney M, Ng TY, Tam K, Chan K, Wrede CD, Pather S, Simcock B, Farrell R, Obermair A.
    Lancet Oncol; 2010 Aug 06; 11(8):772-80. PubMed ID: 20638899
    [Abstract] [Full Text] [Related]

  • 33. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR.
    Lancet Oncol; 2018 Aug 06; 19(8):1117-1125. PubMed ID: 30026000
    [Abstract] [Full Text] [Related]

  • 34. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L.
    Lancet Oncol; 2015 Mar 06; 16(3):274-83. PubMed ID: 25656287
    [Abstract] [Full Text] [Related]

  • 35. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial).
    Hopwood P, Haviland J, Mills J, Sumo G, M Bliss J, START Trial Management Group.
    Breast; 2007 Jun 06; 16(3):241-51. PubMed ID: 17236771
    [Abstract] [Full Text] [Related]

  • 36. Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer.
    Cao L, Ou D, Shen KW, Cai G, Cai R, Xu F, Zhao SG, Xu C, Grellier Adedjouma N, Kirova YM, Chen JY.
    Cancer Radiother; 2018 Feb 06; 22(1):38-44. PubMed ID: 29306555
    [Abstract] [Full Text] [Related]

  • 37. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L.
    Lancet Oncol; 2016 Apr 06; 17(4):464-474. PubMed ID: 26968359
    [Abstract] [Full Text] [Related]

  • 38. Quality of life and patient satisfaction after one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage breast reconstruction (BRIOS): primary outcome of a randomised, controlled trial.
    Negenborn VL, Young-Afat DA, Dikmans REG, Smit JM, Winters HAH, Don Griot JPW, Twisk JWR, Ruhé PQ, Mureau MAM, Lapid O, Moerman E, van Turnhout AAWM, Ritt MJPF, Bouman MB, Mullender MG.
    Lancet Oncol; 2018 Sep 06; 19(9):1205-1214. PubMed ID: 30104147
    [Abstract] [Full Text] [Related]

  • 39. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z.
    Eur J Surg Oncol; 2017 Apr 06; 43(4):672-679. PubMed ID: 28139362
    [Abstract] [Full Text] [Related]

  • 40. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Reijneveld JC, Taphoorn MJB, Coens C, Bromberg JEC, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG.
    Lancet Oncol; 2016 Nov 06; 17(11):1533-1542. PubMed ID: 27686943
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.